We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
Boryung Pharmaceutical said that it has signed an exclusive marketing agreement with SN BioScience to market the latter's SNB-101, the world's first nanoparticle anticancer therapy.
